Literature DB >> 25011945

Cultures of diabetic foot ulcers without clinical signs of infection do not predict outcomes.

Sue E Gardner1, Ambar Haleem2, Ying-Ling Jao3, Stephen L Hillis4, John E Femino5, Phinit Phisitkul5, Kristopher P Heilmann2, Shannon M Lehman3, Carrie L Franciscus6.   

Abstract

OBJECTIVE: We examined associations between ulcer bioburden and ulcer outcomes in neuropathic diabetic foot ulcers (DFUs) that lacked clinical signs of infection. RESEARCH DESIGN AND METHODS: Three dimensions of bioburden (i.e., microbial load, microbial diversity, and the presence of likely pathogens) were measured at baseline using swab cultures obtained by Levine's technique. Subjects were assessed every 2 weeks for 26 weeks to determine the rate of healing and development of infection-related complications. Foot ulcers were off-loaded using total-contact casts and routinely debrided. To establish associations between bioburden and rate of healing, Cox proportional hazards and least squares regression were used after adjusting for ulcer depth, surface area, and duration.
RESULTS: A total of 77 subjects completed the study. Sixty-five (84.4%) had ulcers that healed during follow-up; weeks-to-closure ranged from 2 to 26 (median 4.0). Mean (± SD) percent reduction in surface area/week was 25.0% (± 23.33). Five (6.5%) of the DFUs developed an infection-related complication. None of the bioburden dimensions (i.e., microbial load, microbial diversity, or presence of likely pathogens) was significantly associated with weeks-to-closure or percent reduction in surface area per week. Weeks-to-closure was best predicted by ulcer duration, depth, and surface area (c-statistic = 0.75).
CONCLUSIONS: Culturing DFUs that showed no clinical signs of infection had no predictive value for outcomes of DFUs managed with total-contact casts and routine debridement. These findings support recommendations of the Infectious Disease Society of America that culturing and antibiotics should be avoided in treating DFUs that show no clinical signs of infection.
© 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25011945      PMCID: PMC4170124          DOI: 10.2337/dc14-0051

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  32 in total

1.  Guidelines for the treatment of diabetic ulcers.

Authors:  David L Steed; Christopher Attinger; Theodore Colaizzi; Mary Crossland; Michael Franz; Lawrence Harkless; Andrew Johnson; Hans Moosa; Martin Robson; Thomas Serena; Peter Sheehan; Aristidis Veves; Laurel Wiersma-Bryant
Journal:  Wound Repair Regen       Date:  2006 Nov-Dec       Impact factor: 3.617

2.  Rapid detection and identification of metallo-beta-lactamase-encoding genes by multiplex real-time PCR assay and melt curve analysis.

Authors:  Rodrigo E Mendes; Katia A Kiyota; Jussimara Monteiro; Mariana Castanheira; Soraya S Andrade; Ana C Gales; Antonio C C Pignatari; Sergio Tufik
Journal:  J Clin Microbiol       Date:  2006-11-08       Impact factor: 5.948

3.  What is bioburden? The link to chronic wounds.

Authors:  Richard Salcido
Journal:  Adv Skin Wound Care       Date:  2007-07       Impact factor: 2.347

Review 4.  Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.

Authors:  F E Harrell; K L Lee; D B Mark
Journal:  Stat Med       Date:  1996-02-28       Impact factor: 2.373

Review 5.  Diagnostics and treatment of the diabetic foot.

Authors:  Jan Apelqvist
Journal:  Endocrine       Date:  2012-02-25       Impact factor: 3.633

6.  Causal pathways for incident lower-extremity ulcers in patients with diabetes from two settings.

Authors:  G E Reiber; L Vileikyte; E J Boyko; M del Aguila; D G Smith; L A Lavery; A J Boulton
Journal:  Diabetes Care       Date:  1999-01       Impact factor: 19.112

7.  High bacterial load in asymptomatic diabetic patients with neurotrophic ulcers retards wound healing after application of Dermagraft.

Authors:  A C Browne; M Vearncombe; R G Sibbald
Journal:  Ostomy Wound Manage       Date:  2001-10       Impact factor: 2.629

8.  Clinical signs of infection in diabetic foot ulcers with high microbial load.

Authors:  Sue E Gardner; Stephen L Hillis; Rita A Frantz
Journal:  Biol Res Nurs       Date:  2009-10       Impact factor: 2.522

9.  Qualitative bacteriology and leg ulcer healing.

Authors:  N J Trengove; M C Stacey; D F McGechie; S Mata
Journal:  J Wound Care       Date:  1996-06       Impact factor: 2.072

10.  The neuropathic diabetic foot ulcer microbiome is associated with clinical factors.

Authors:  Sue E Gardner; Stephen L Hillis; Kris Heilmann; Julia A Segre; Elizabeth A Grice
Journal:  Diabetes       Date:  2012-11-08       Impact factor: 9.461

View more
  10 in total

Review 1.  Biology and Biomarkers for Wound Healing.

Authors:  Linsey E Lindley; Olivera Stojadinovic; Irena Pastar; Marjana Tomic-Canic
Journal:  Plast Reconstr Surg       Date:  2016-09       Impact factor: 4.730

2.  Strain- and Species-Level Variation in the Microbiome of Diabetic Wounds Is Associated with Clinical Outcomes and Therapeutic Efficacy.

Authors:  Lindsay R Kalan; Jacquelyn S Meisel; Michael A Loesche; Joseph Horwinski; Ioana Soaita; Xiaoxuan Chen; Aayushi Uberoi; Sue E Gardner; Elizabeth A Grice
Journal:  Cell Host Microbe       Date:  2019-04-18       Impact factor: 21.023

Review 3.  Challenges and innovations in treating chronic and acute wound infections: from basic science to clinical practice.

Authors:  Xiaotong Ding; Qinghan Tang; Zeyu Xu; Ye Xu; Hao Zhang; Dongfeng Zheng; Shuqin Wang; Qian Tan; Joanneke Maitz; Peter K Maitz; Shaoping Yin; Yiwei Wang; Jun Chen
Journal:  Burns Trauma       Date:  2022-05-21

4.  Preliminary Experience with Conservative Sharp Wound Debridement by Nurses in the Outpatient Management of Diabetic Foot Ulcers: Safety, Efficacy, and Economic Analysis.

Authors:  Ross A Schumer; Brian L Guetschow; Marissa V Ripoli; Phinit Phisitkul; Sue E Gardner; John E Femino
Journal:  Iowa Orthop J       Date:  2020

Review 5.  Microbiology of diabetic foot infections: from Louis Pasteur to 'crime scene investigation'.

Authors:  Anne Spichler; Bonnie L Hurwitz; David G Armstrong; Benjamin A Lipsky
Journal:  BMC Med       Date:  2015-01-07       Impact factor: 8.775

Review 6.  The dynamic wound microbiome.

Authors:  Chunan Liu; Alise J Ponsero; David G Armstrong; Benjamin A Lipsky; Bonnie L Hurwitz
Journal:  BMC Med       Date:  2020-11-24       Impact factor: 8.775

7.  Impact of Rejection of Low-Quality Wound Swabs on Antimicrobial Prescribing: A Controlled Before-After Study.

Authors:  Xavier Marchand-Senécal; Ian A Brasg; Robert Kozak; Marion Elligsen; Christie Vermeiren; Antoine J Corbeil; Kevin R Barker; Kevin Katz; Jeff E Powis; Wayne L Gold; Jerome A Leis
Journal:  Open Forum Infect Dis       Date:  2020-12-13       Impact factor: 3.835

Review 8.  The Gut-Skin Microbiota Axis and Its Role in Diabetic Wound Healing-A Review Based on Current Literature.

Authors:  Bharati Kadamb Patel; Kadamb Haribhai Patel; Ryan Yuki Huang; Chuen Neng Lee; Shabbir M Moochhala
Journal:  Int J Mol Sci       Date:  2022-02-21       Impact factor: 5.923

9.  Microbiome Characterization of Infected Diabetic Foot Ulcers in Association With Clinical Outcomes: Traditional Cultures Versus Molecular Sequencing Methods.

Authors:  Hadar Mudrik-Zohar; Shaqed Carasso; Tal Gefen; Anat Zalmanovich; Michal Katzir; Yael Cohen; Yossi Paitan; Naama Geva-Zatorsky; Michal Chowers
Journal:  Front Cell Infect Microbiol       Date:  2022-03-24       Impact factor: 5.293

10.  Association between baseline abundance of Peptoniphilus, a Gram-positive anaerobic coccus, and wound healing outcomes of DFUs.

Authors:  Kyung R Min; Adriana Galvis; Katherine L Baquerizo Nole; Rohita Sinha; Jennifer Clarke; Robert S Kirsner; Dragana Ajdic
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.